RBMS1 (RNA Binding Motif Single Stranded Interacting Protein 1)

RBMS1 is aberrantly overexpressed in gliomas, associated with tumor aggressiveness, immunosuppressive microenvironment remodeling, and poor prognosis, positioning it as a promising prognostic biomarker and therapeutic target.

This study suggests that RBMS1 regulates HSPA8 to promote the proliferation, migration, and invasion of HNSCC cells, making it a potential therapeutic target for HNSCC.

Specifically, RBMS1 increased the expression of SSH1, which is also upregulated in glioma patient specimens, by inducing c-Myc binding to SSH1 promoters. Our results indicate that the RBMS1-c-Myc-SSH1 axis plays a crucial role in controlling behaviors related to glioma cell proliferation and tumor growth.

Two small molecule drugs targeting SAT1, namely Argatroban and Menadione, were predicted. Moreover, their therapeutic potentials in the treatment of UV-irradiated skin injury were confirmed experimentally.

Collectively, this study revealed that RBMS1 silence inhibited the malignant progression of GBM possibly through ferroptosis.

Biological experiments were performed and demonstrated that the silencing of RBMS1 inhibited ocular melanoma proliferation and promoted apoptosis. Our study highlighted that RBMS1 reflects a distinct microenvironment and promotes tumor progression in ocular melanoma, contributing to the therapeutic customization and clinical decision-making.

Validation of clinical specimens revealed that RBMS1 is similarly linked to tumor development and a poor prognosis. Overall, RBMS1 is a potential therapeutic target with clinical translational potential, particularly for oxaliplatin chemoresistance in colorectal cancer.

More importantly, a novel circIDE (hsa_circ_0000251) was identified to elevate RBMS1 expression via sponging miR-19b-3p in HCC cells. Collectively, our findings established circIDE/miR-19b-3p/RBMS1 axis as a regulator of ferroptosis, which could be a promising therapeutic target and prognostic factor.